Intra-Cellular Therapies' GAAP loss for 3 months of 2022 was $72.119 million, up 36.7% from $52.74 million in the prior year. Revenue increased 2.2-fold to $34.996 million from $15.878 million a year earlier.
Intra-Cellular Therapies' GAAP loss for 3 months of 2022 was $72.119 million, up 36.7% from $52.74 million in the prior year. Revenue increased 2.2-fold to $34.996 million from $15.878 million a year earlier. 
ir.intracellulartherapies.com
English (US) 